Rein Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
RNTX Nasdaq 2834 www.reintx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rein Therapeutics Inc.

Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF - Nov 6th, 2025 5:30 am
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - Nov 3rd, 2025 5:30 am
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - Oct 9th, 2025 5:30 am
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis - Sep 17th, 2025 5:30 am
Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls - Aug 19th, 2025 7:32 am
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - Aug 19th, 2025 6:00 am
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - Aug 14th, 2025 3:00 pm
Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing - Jul 30th, 2025 6:30 am
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - Jun 24th, 2025 8:11 am
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - May 27th, 2025 5:00 am
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference - May 19th, 2025 2:51 pm
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - May 15th, 2025 2:09 pm
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - May 12th, 2025 5:00 am
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - May 1st, 2025 5:00 am
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - Apr 30th, 2025 2:05 pm
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference - Apr 28th, 2025 5:00 am
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases - Apr 23rd, 2025 5:00 am
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - Apr 15th, 2025 5:00 am
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Apr 7th, 2025 2:17 pm